Vaccinated for COVID-19 Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
The study shall include 50 healthy volunteers eligible for vaccination for COVID-19. These volunteers will be screened for Absolute Lymphocyte Count (CD3+, CD4+ and CD8+) and Anti SARS-CoV-2 spike pro
Sponsors
Shreepad Shree Vallabh SSV Phytopharmaceuticals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult male or female human volunteer of age 18-65 years (inclusive) 2. Eligible for vaccination for COVID-19 3. Willing and able to provide written, signed and dated informed consent 4. Had no medical history or evidence of COVID-2019 5. Had no acute infections and/or respiratory diseases within 14 days before enrollment. 6. Had no evidence of vaccine-induced reactions or complications after receiving immunobiological products in the past medical history. 7. Willing to give consent to use effective contraception methods during the study 8. Have a negative urine pregnancy test at the screening visit (for child-bearing aged women) 9. Have negative human immunodeficiency virus (HIV 1 & 2), syphilis, hepatitis B and C test results
Exclusion criteria
Exclusion criteria: 1. Aged 65 years 2. Any vaccination/immunization within 30 days before the enrollment 3. Any treatment with steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products within 30 days before the enrollment 4. Any treatment with immunosuppressive therapy within 3 months before the enrollment 5. Any drug allergy (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on enrollment day 6. Any neoplasms in the past medical history 7. Donated blood or plasma within 3 months before the enrollment 8. Any history or evidence of splenectomy 9. Any immunodeficiency state 10. Any history or evidence of anorexia or protein deficiency of any origin 11. Alcohol or drug addiction in the past medical history 12. Participation in any other interventional clinical trial within 3 months 13. Any other condition that the study physician considers as a barrier to the trial completion as per the protocol 14. Pregnancy or breast-feeding 15. Subjects who are tested positive for Coronavirus disease through RT-PCR SARS CoV-2 Test and positive anti-COVID antibodies within 3 months before the enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured by blood test at baseline and 120 days: 1. Absolute lymphocyte count (CD3+, CD4+ and CD8+) 2. Anti-SARS-CoV-2 spike protein (S1 /S2) IgG | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of Curvic® with or without vaccine assessed through clinical biochemistry and by symptomatology at baseline and 120 days | — |
Countries
India
Outcome results
None listed